We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Warns California Drugmaker for Sourcing from Sub-Standard CMOs
FDA Warns California Drugmaker for Sourcing from Sub-Standard CMOs
The FDA issued a warning letter to United Exchange Corp. for serious quality violations, including using products from “multiple sub-standard contract manufacturers” at its Cypress and Rialto drug manufacturing plants.